The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.
Click Search to look for specific questions in SINQ or to select questions for a Report .
If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.
Recent Questions
Add to Report
ID
Question
Status
Last Updated
Add to Report
20180082
Summary Stage Manual 2018—Lymphoma: SEER Summary Stage 2000 states: For lymphomas, any mention of lymph nodes is indicative of involvement and is used to determine the number and location of lymph node chains involved (see lymphoma scheme). This statement is not in SEER Summary Stage 2018. Does that mean we follow rules #4-7, pages 14-15, under Code 3: Regional Lymph Nodes only, for every site, including lymphoma?
Final
Sep 20 2018
Add to Report
20180081
Reportability--Corpus uteri: Is endometrial atypical complex hyperplasia/borderline endometrial adenocarcinoma (FIGO 1), (mucinous type), (no invasion of myometrium) reportable?
Final
Sep 20 2018
Add to Report
20180079
Solid Tumor Rules/Multiple primaries--Breast: How many primaries should be abstracted when papillary carcinoma is identified in two biopsies and a subsequent lumpectomy identified invasive ductal carcinoma with multifocal ductal carcinoma in situ (DCIS)? See Discussion.
Final
Sep 11 2018
Add to Report
20180071
Solid Tumor Rules (2018)/Histology--Cervix uteri: What is the correct histology code for malignant mixed Mullerian tumor (MMMT/Carcinosarcoma)? See Discussion.
Final
Aug 31 2018
Add to Report
20180070
Solid Tumor Rules (2018)/Histology--Lung: The Histology coding guidelines for lung cancer state to code histology when stated as type or subtype but not to code when described as pattern. How should the histology be coded (Adeno, NOS or Adeno, Mixed subtypes) if the College of Americal Pathologists Protocol of the pathology report lists the following: Histologic type: Adenocarcinoma, papillary (90%), lepidic (8%), and solid (2%) patterns?
Final
Aug 31 2018
Add to Report
20180065
Immunotherapy: Is immunotherapy ever palliative treatment according to any oncologists or SEER?
Final
Aug 28 2018
Add to Report
20180064
Solid Tumor Rules (2018)/Recurrence--Breast: Does any recurrence within the multiple primaries-stated timeframe count, not those just in the primary site? See Discussion.
Final
Aug 28 2018
Add to Report
20180062
Histology--Heme & Lymphoid Neoplasms: How is histology coded when a lymph node excisional biopsy shows Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), predominantly in diffuse T-cell histiocyte rich large B-cell lymphoma-like (THRLBCL) pattern. Comment states: The findings are that of nodular lymphocyte predominant Hodgkin lymphoma with diffuse T-cell rich pattern (T-cell/histiocyte-rich large B-cell lymphoma-like). This variant is regarded as clinically more advanced. See Discussion.
Final
Aug 13 2018
Add to Report
20180061
Primary Site: How should primary site be coded when there is an invasive tumor in one subsite and an in situ tumor in another subsite of the breast? See Discussion.
Final
Aug 09 2018
Add to Report
20180056
Primary Site--Ovary: How should primary site be coded for a previously diagnosed ovarian cancer which is now being reclassified as fallopian tube? See Discussion.
Final
Aug 01 2018
Next 10 >